Two Law Firms Steer as KKR-Backed Biopharma Unit Buys Vivitide - Bloomberg Law

Gibson, Dunn & Crutcher advised KKR on the acquisition of Vivitide Inc. by the global investor’s new life sciences portfolio company Biosynth Carbosynth.

Vivitide is a Gardner, Massachusetts-based maker of custom peptides and antibodies for the biotech industry.

McDermott Will & Emery said it represented Ampersand Capital Partners, Vivitide’s previous owner, which will roll over its entire stake and retain a “substantial” minority stake in the combined company.

Together, KKR and Ampersand plan to accelerate the combined company’s geographic expansion, broaden its capabilities, and expand its product portfolio, according to a statement.

“This acquisition marks an important milestone in our ambitious journey to become a leading global partner providing critical materials to the biopharma and diagnostics industries,” said Dr. Urs Spitz, CEO and president of Biosynth Carbosynth, in a statement.

Gibson Dunn said it also advised KKR on the closing of its investment in Biosynth Carbosynth, which was announced November 2021.

To contact the correspondent on this story: Rick Mitchell in Paris at [email protected]

To contact the editor on this story: Chris Opfer in New York at [email protected] John Hughes in Washington at [email protected]

source: https://news.bloomberglaw.com/business-and-practice/two-law-firms-steer-as-kkr-backed-biopharma-unit-buys-vivitide

Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.